Prostate-specific antigen screening, why have the guidelines changed? - Abstract

Prostate cancer (PCa) constitutes a major health issue of the western world given its increasing rate of diagnosis and the fact that it is the second cause of cancer-related death among men.

Although the incidence of PCa is rising, deaths from PCa are at the same time declining. This phenomenon has been largely attributed to the implementation of PCa screening. However PCa screening, which is mainly performed through serum prostate-specific antigen measurement, does not have the desired diagnostic accuracy. This results in a substantial proportion of men undergoing unnecessary biopsies and consequently given therapies for low-risk cancers that will have no effect in prolonging life and might as well only add morbidity. The current report will discuss the pros and cons of PCa screening in light of the recent modifications in the guidelines regarding the early diagnosis of PCa.

Written by:
Sountoulides P, Moutzouris G.   Are you the author?
Urology Department, General Hospital of Veria, Greece.

Reference: Expert Rev Anticancer Ther. 2014 Nov;14(11):1277-81.
doi: 10.1586/14737140.2014.971111


PubMed Abstract
PMID: 25306859

UroToday.com Prostate Cancer Section

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe